OBJECTIVE:To study the protective effects of Danshen injection on 5/6 nephrectomiy induced model rats with in-flammatory renal injury. METHODS:50 rats were equally randomized into a sham-operation (isometric distilled water) group,a model (isometric distilled water) group,a positive control [captopril 5 mg/(kg·d)] group and Danshen injection low-dose and high-dose [1.6,4.8 ml/(kg·d)] groups. Models were established by performing 5/6 nephrectomy on the rats in all groups except the sham-operation group. The rats were given drugs for 4 consecutive weeks from the 6th week. 24 h urine protein was determined for all rats every week. After the last administration,the contents of creatinine,urea nitrogen and interleukins 1β(IL-1β),IL-2 and IL-10 in rats’serum were determined. Pathological changes and infiltration of macrophages CD68 in rats’kidney tissues were ob-served. RESULTS:Compared to the sham-operation group,those in the model group had more 24 h urine protein and more obvi-ous renal pathologic changes during 1-4 weeks of administration,and higher contents of creatinine,urea nitrogen,IL-1β,IL-2 and IL-10 and CD68 positive expression in serum. Compared to the model group,during 2-4 weeks of administration,those in the posi-tive control group and Danshen injection low-dose and high-dose groups had less 24 h urine protein,milder renal pathologic chang-es,and lower contents of creatinine,urea nitrogen,IL-1β and CD68 positive expression in serum,and higher content of IL-10, and only the rats in the positive control group demonstrated lower IL-2 content. There of the above were statistical differences(P<0.01 or P<0.05). CONCLUSIONS:Danshen injection can alleviate renal pathologic changes and reduce inflammatory injury of the kidneys of 5/6 nephrectomiy induced model rats.

Objective:To observe the long-term efficacy and late adverse reactions of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for mediastinal lymph node recurrence after radical surgery for esophageal squamous cell carcinoma (ESCC).Methods:A total of 20 ESCC patients with mediastinal lymph node recurrence (≤5) after radical surgery admitted to Department of Radiotherapy, Shanghai Ruijin Hospital between June 2019 and December 2021 were enrolled in this prospective study. Among them, 10 patients were enrolled in phase I study and 10 patients in phase II study. Four, 3 and 13 patients received three different doses of SIB-IMRT at 58.8 Gy/28 fractions, 64.4 Gy/28 fractions and 70.0 Gy/28 fractions for recurrent lesions, respectively. The overall survival (OS) rate, local control rate (LCR) and progression-free survival (PFS) were calculated by Kaplan-Meier analysis. Adverse reactions were also analyzed.Results:The most common sites of recurrence were 2R and 4 L, accounting for 35% and 25%, respectively. The median follow-up time was 32 months. For patients who received salvage chemoradiation after relapse, the 1-, 2- and 3-year OS rates were 100%, 88% and 78%, the 1-, 2- and 3-year PFS rates were 85%, 78% and 78%, respectively. The most common hematological toxicities were leukocytopenia and anemia. The most common nonhematological toxicity was esophagitis. However, no grade 3 or above esophagitis, pneumonia and cardiotoxicity were found. Three patients who received SIB-IMRT at 58.8 Gy/28 fractions died of distant metastases at 2 years after treatment, and 1 patient who received SIB-IMRT at 70.0 Gy/28 fractions died of distant metastases at 16 months after treatment.Conclusion:Salvage chemoradiotherapy using SIB-IMRT is efficacious and safe for mediastinal lymph node recurrence in ESCC patients after radical resection.